Abaloparatide in men with osteoporosis (ATOM) study results: a plain language summary
Bibliographic record
Abstract
SummaryWhat is this summary about? This is a summary of a clinical research study, which included men with osteoporosis to determine the efficacy (the ability of a medication to produce a desired effect or how “effective” the medication is) and safety of an injectable osteoporosis medication called abaloparatide (brand name Tymlos®). The study compared abaloparatide treatment to treatment with a placebo. The placebo injection was designed to look identical to abaloparatide but did not have an active ingredient.The US Federal Drug Administration (FDA) is a regulatory body that approved abaloparatide for the treatment of women who have been through menopause (postmenopausal women) with osteoporosis at high risk for breaking bones (also called “fractures”). The hormone estrogen, which is important for bone formation, is reduced after menopause, leading to an increased risk of osteoporosis. As a result of the ATOM study, abaloparatide is now also FDA approved to increase bone mineral density in men with osteoporosis at high risk of fractures. This summary includes a patient perspective on the study publication.What were the results? The study showed that treatment with abaloparatide resulted in an increase in bone mineral density in men with osteoporosis when compared to placebo, which was similar to that seen in women with osteoporosis.What do the results of the study mean? Abaloparatide increased bone mineral density in men at high risk of fracture. An increase in bone mineral density suggests an improvement in bone strength and potentially fewer fractures.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.012 | 0.031 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.004 | 0.004 |
| Bibliometrics | 0.003 | 0.004 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.004 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.003 |
| Insufficient payload (model declined to judge) | 0.023 | 0.007 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".